Nearly 1,000 GLP-1 Lawsuits Allege Failure-to-Warn Vision Loss

For mass tort and product liability attorneys, the GLP-1 litigation is shaping up as the next major pharmaceutical failure-to-warn battleground. With nearly 1,000 cases filed in New Jersey alone and disparate warning labels across jurisdictions, the central dispute will be whether current U.S. labeling was adequate and whether the FDA's ongoing investigation changes the preemption analysis.

A wave of product-liability litigation is building against Novo Nordisk and Eli Lilly after reports that their blockbuster GLP-1 receptor agonist drugs may be associated with nonarteritic anterior ischemic optic neuropathy, or NAION, a rare condition that can cause sudden and permanent vision loss. The litigation, first reported by The Wall Street Journal on September 22, 2026, includes dozens of federal personal-injury suits against Novo Nordisk over Ozempic and Wegovy and similar cases against Eli Lilly over Zepbound and Mounjaro. USA Today puts the broader scope far higher, reporting nearly 1,000 cases filed in New Jersey alone over the past year. The central allegation is a classic pharmaceutical failure-to-warn claim: that U.S. labeling did not disclose the potential ophthalmic risk even though warning labels in some other countries do. The FDA is investigating the potential link and will decide whether regulatory action is needed.

“

The Cleveland Clinic describes it as painless and sudden, often noticed after long sleeps or naps, with blurring or darkening typically in the lower half of vision; roughly 15% of patients eventually develop it in the other eye.

NAION occurs when reduced blood flow to the optic nerve causes tissue damage. The Cleveland Clinic describes it as painless and sudden, often noticed after long sleeps or naps, with blurring or darkening typically in the lower half of vision; roughly 15% of patients eventually develop it in the other eye. It usually affects people over 50 and has no approved treatment, according to the American Academy of Ophthalmology. Those features make the alleged injury particularly serious: patients may wake up with compromised vision and face fewer therapeutic options than with many other adverse events. The lawsuits claim patients should have been told about this risk, and the absence of a U.S. label warning is central to the litigation.

The scientific picture remains unsettled. A 2025 study that followed more than 159,000 American adults with type 2 diabetes over two years found 35 GLP-1 users developed NAION, compared with 19 in a comparison group. Researchers also identified 93 patients with other optic nerve disorders. The same analysis noted a modestly increased risk of diabetic retinopathy but concluded that fewer patients on GLP-1s experienced sight-threatening complications, underscoring a nuanced risk-benefit profile. The American Academy of Ophthalmology's 2025 news release did not call for halting therapy but encouraged clinicians and patients to make informed choices. No study has yet proven causation, and the rare absolute incidence means the signal may remain statistically fragile.